ERBB2 and breast carcinoma: A meta-analysis of 5 trials (CHER-LOB, GeparQuattro, GeparQuinto, GeparSixto and Neo-ALTTO) involving neo-adjuvant treatment of HER2+ breast cancer with trastuzumab and chemotherapy (n = 1256) showed a significant correlation between high baseline TILs and achieving a pCR [53].